Structure Therapeutics, Inc. Sponsored ADR (GPCR) Price & Analysis

Compare

1,197 Followers

GPCR Stock Chart & Stats

$78.93

-$0.32(-1.18%)

At close: Jan 08 4:00 PM EST

$78.93

-$0.32(-1.18%)

Day’s Range― - ―

52-Week Range$13.22 - $94.90

Previous CloseN/A

Volume219.80K

Average Volume (3M)1.09M

Market Cap

$5.55B

Enterprise Value$4.31B

Total Cash (Recent Filing)$799.04M

Total Debt (Recent Filing)$7.09M

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Mar 26, 2026

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding70,639,190

10 Day Avg. Volume991,645

30 Day Avg. Volume1,092,092

Financial Highlights & Ratios

PEG Ratio3.15

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-12.11

Enterprise Value/Market Cap0.78

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-6.27K

Enterprise Value/Ebitda-18.08

Forecast

1Y Price Target

$106.50

Price Target Upside34.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)-1.38

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Business Development And Strategic InterestHigh industry demand for obesity assets and active partnership discussions increase the likelihood of strategic deals or acquisitions that could accelerate development and drive value realization.

Efficacy And Tolerability ProfilePositive clinical data show aleniglipron achieves competitive weight-loss results with improved GI tolerability and no liver safety signal, supporting its case as a viable oral GLP-1 therapy.

Intellectual Property And LicensingGranting a freedom-to-operate license to a major pharmaceutical company and receiving upfront payments and royalties highlights robust patent protection and commercial value for the company’s oral GLP-1 scaffolds.

Bears Say

Competition From Faster Oral PeptidesEmerging oral peptide competitors that reach therapeutic doses more quickly and deliver stronger weight loss pose a material threat to small-molecule adoption by offering a speed-to-efficacy advantage.

Titration And Real-world Adherence RiskThe need for slower titration with aleniglipron may create adherence challenges in real-world settings, potentially reducing uptake relative to faster-titrating alternatives.

Tolerability Signal—vomiting FrequencyA higher incidence of vomiting reported in the aleniglipron program versus a peer comparator raises tolerability concerns that could complicate regulatory review and commercial acceptance.

Structure Therapeutics, Inc. Sponsored ADR News

Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat

The major averages were broadly lower near noon as tech stocks continue to decline and as investors continue...

13d ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A...

14d ago

GPCR

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

JPMorgan raised the firm’s price target on Structure Therapeutics (GPCR) to $105 from $65 and keeps an Overweight...

22d ago

GPCR

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

Guggenheim raised the firm’s price target on Structure Therapeutics (GPCR) to $140 from $90 and keeps a Buy...

24d ago

GPCR

Structure Therapeutics moved to Buy rating at Goldman Sachs

Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The...

24d ago

LLY

GPCR

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

Shares of several names in the obesity-drug space, including Viking Therapeutics (VKTX), Terns Pharmaceuticals (TERN), and Structure Therapeutics...

29d ago

LLY

NVO

Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports

Novo Nordisk (NVO) is back on the hunt for deals to boost its obesity portfolio after losing U.S....

29d ago

LLY

NVO

Structure Therapeutics rises 14.1%

Structure Therapeutics (GPCR) is up 14.1%, or $9.79 to $79.15. Published first on TheFly – the ultimate source...

1M ago

GPCR

Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating

Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, reducing the...

1M ago

GPCR

Structure Therapeutics inks major GLP-1 licensing deal

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio,...

1M ago

GPCR

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60...

2M ago

GPCR

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

Structure Therapeutics (GPCR) announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s...

2M ago

GPCR

Structure Therapeutics Announces $650 Million Public Offering

An update from Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) is now available. On December 9, 2025,...

2M ago

GPCR

Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk

Biotech Structure Therapeutics’ ($GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped competing...

2M ago

LLY

NVO

GPCR FAQ

What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?

Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.

What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?

Structure Therapeutics, Inc. Sponsored ADR’s market cap is $5.55B.

When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?

Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 26, 2026 which is in 41 days.

How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?

Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, the consensus estimate of -$0.37 by $0.

Is Structure Therapeutics, Inc. Sponsored ADR overvalued?

According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?

Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.

What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?

Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.

How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?

Structure Therapeutics, Inc. Sponsored ADR has 70,639,190 shares outstanding.

What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?

Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.37 in its last earnings report, expectations of -$0.37. Following the earnings report the stock price went down -1.882%.

Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?

Currently, no hedge funds are holding shares in GPCR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-25.31%

Trailing 12-Months

Asset Growth

-10.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Earnings & Revenues

Historic Earnings Reports

GPCR Stock 12 Month Forecast

Average Price Target

$106.50

▲(34.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","141":"$141","45.75":"$45.8","77.5":"$77.5","109.25":"$109.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,45.75,77.5,109.25,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,93.69846153846154,97.55692307692308,101.41538461538462,105.27384615384615,109.13230769230769,112.99076923076923,116.84923076923077,120.70769230769231,124.56615384615384,128.42461538461538,132.28307692307692,136.14153846153846,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,91.12153846153846,92.40307692307692,93.68461538461538,94.96615384615384,96.2476923076923,97.52923076923076,98.81076923076924,100.0923076923077,101.37384615384616,102.65538461538462,103.93692307692308,105.21846153846154,{"y":106.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,87.92923076923077,86.01846153846154,84.1076923076923,82.19692307692308,80.28615384615385,78.37538461538462,76.46461538461539,74.55384615384615,72.64307692307693,70.7323076923077,68.82153846153847,66.91076923076923,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >